[{"orgOrder":0,"company":"Phaxiam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PP1493","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Phaxiam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Phaxiam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Phaxiam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phaxiam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PP1493","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Phaxiam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Phaxiam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Phaxiam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phaxiam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"Staphylococcus Aureus Bacteriophages","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Phaxiam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Phaxiam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Phaxiam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Phaxiam Therapeutics","sponsor":"Erytech Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Large Molecule","year":"2023","type":"Merger","leadProduct":"PhagoDAIR","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Phaxiam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Phaxiam Therapeutics \/ Erytech Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Phaxiam Therapeutics \/ Erytech Pharma"},{"orgOrder":0,"company":"Pherecydes Pharma","sponsor":"Erytech Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pherecydes Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Pherecydes Pharma \/ Erytech Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Pherecydes Pharma \/ Erytech Pharma"},{"orgOrder":0,"company":"Valneva","sponsor":"LimmaTech Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Shigella4V2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ LimmaTech Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ LimmaTech Biologics"},{"orgOrder":0,"company":"Valneva","sponsor":"LimmaTech Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Shigella4V2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Valneva \/ LimmaTech Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ LimmaTech Biologics"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SP0202","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Center for Vaccinology, University of Ghent","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Osivax \/ Center for Vaccinology, University of Ghent","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Center for Vaccinology, University of Ghent"},{"orgOrder":0,"company":"Osivax","sponsor":"Northern Beaches Clinical Research | Novotech | Harmony Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Osivax \/ Northern Beaches Clinical Research | Novotech | Harmony Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Northern Beaches Clinical Research | Novotech | Harmony Clinical Research"},{"orgOrder":0,"company":"Osivax","sponsor":"H\u00f4pital Cochin | Clinact","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Osivax \/ H\u00f4pital Cochin | Clinact","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ H\u00f4pital Cochin | Clinact"},{"orgOrder":0,"company":"Osivax","sponsor":"Novotech | Mater Misericordiae Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Osivax \/ Novotech | Mater Misericordiae Limited","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Novotech | Mater Misericordiae Limited"},{"orgOrder":0,"company":"Osivax","sponsor":"Harmony Clinical Research | Clinfidence | Inferential | University Hospital Ghent | KCAS Bio","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Osivax \/ Harmony Clinical Research | Clinfidence | Inferential | University Hospital Ghent | KCAS Bio","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Harmony Clinical Research | Clinfidence | Inferential | University Hospital Ghent | KCAS Bio"},{"orgOrder":0,"company":"Osivax","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Osivax","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ European Innovation Council","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ European Innovation Council"},{"orgOrder":0,"company":"Osivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Inactivated Quadrivalent Influenza Vaccine","moa":"||Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Inapplicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Influenza Vaccine","moa":"||Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Inapplicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"OVX836","moa":"||Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Inapplicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Inapplicable"},{"orgOrder":0,"company":"Osivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Inapplicable"},{"orgOrder":0,"company":"Osivax","sponsor":"KM Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ KM Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ KM Biologics"},{"orgOrder":0,"company":"Osivax","sponsor":"Meiji Seika Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Series B Financing","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Meiji Seika Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"Osivax","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"OVX836","moa":"||Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Bpifrance","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Bpifrance"},{"orgOrder":0,"company":"Osivax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"OVX836","moa":"||Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ Inapplicable"},{"orgOrder":0,"company":"Osivax","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"OVX836","moa":"||Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Osivax \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ National Institutes of Health"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Multivalent Pneumococcal conjugate vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Liquid","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine","moa":"RSV","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Multivalent Pneumococcal conjugate vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"4P-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Plerixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"4P-Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4P-Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"4P-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Oxaquin","moa":"DNA topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SAS \/ Inapplicable"},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Oxaquin","moa":"DNA topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SAS \/ Inapplicable"},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Oxaquin","moa":"DNA topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SAS \/ Inapplicable"},{"orgOrder":0,"company":"Deinove SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Oxaquin","moa":"DNA topoisomerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Deinove SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Deinove SAS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Deinove SAS \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avdoralimab","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Avdoralimab","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Avdoralimab","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Innate Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Innate Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Innate Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inotrem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Inapplicable"},{"orgOrder":0,"company":"Inotrem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Inapplicable"},{"orgOrder":0,"company":"Inotrem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inotrem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Inapplicable"},{"orgOrder":0,"company":"4P-Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Plerixafor","moa":"C-X-C chemokine receptor type 4","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"4P-Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4P-Pharma \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"4P-Pharma \/ Sanofi"},{"orgOrder":0,"company":"Enyo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"EYP001a","moa":"FXR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enyo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enyo Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enyo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Enyo Pharma","sponsor":"Novotech | Syneos Health | Eurofins CDMO | Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"EYP001a","moa":"FXR","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enyo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Enyo Pharma \/ Novotech | Syneos Health | Eurofins CDMO | Parexel","highestDevelopmentStatusID":"8","companyTruncated":"Enyo Pharma \/ Novotech | Syneos Health | Eurofins CDMO | Parexel"},{"orgOrder":0,"company":"MedinCell","sponsor":"Violaine Desort-H\u00e9nin, DVM","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MedinCell \/ Violaine Desort-H\u00e9nin, DVM","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell \/ Violaine Desort-H\u00e9nin, DVM"},{"orgOrder":0,"company":"AB Science","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ European Investment Bank","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ European Investment Bank"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"University of Chicago","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Masitinib Mesylate","moa":"||3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AB Science \/ University of Chicago","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ University of Chicago"},{"orgOrder":0,"company":"DaVolterra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"DAV132","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"DaVolterra","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"DaVolterra \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"DaVolterra \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Lunsekimig","moa":"IL13","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Lunsekimig","moa":"IL13","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Yellow Fever Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Yellow Fever Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Itepekimab","moa":"Interleukin-33","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Phaxiam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"PP1493","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Phaxiam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phaxiam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Phaxiam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor | Stem cell growth factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"AB Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Masitinib Mesylate","moa":"Fibroblast growth factor receptor 3 | Platelet-derived growth factor receptor | Stem cell growth factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"AB Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AB Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AB Science \/ Inapplicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"MedinCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell \/ Inapplicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"MedinCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell \/ Inapplicable"},{"orgOrder":0,"company":"Inotrem","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Nangibotide","moa":"Triggering receptor expressed on myeloid cells 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Inotrem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inotrem \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inotrem \/ Inapplicable"},{"orgOrder":0,"company":"Valneva","sponsor":"LimmaTech Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Shigella4V2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ LimmaTech Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Valneva \/ LimmaTech Biologics"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Respiratory Syncytial Virus Vaccine","moa":"RSV","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Suspension","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedinCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell \/ Inapplicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"MedinCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell \/ Inapplicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"MedinCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell \/ Inapplicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"MedinCell \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MedinCell \/ Inapplicable"},{"orgOrder":0,"company":"Osivax","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Funding","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Osivax","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Osivax \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"Osivax \/ BARDA"}]
Find Drugs for Infections and Infectious Diseases in Phase II Clinical Development in FRANCE
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
